Suggested remit: To appraise the clinical and cost effectiveness of veliparib within its marketing authorisation for treating BRCA-positive, human epidermal growth factor 2 (HER2)-negative, breast advanced cancer.
For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Process STA 2018
ID number 1404

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
06 April 2021 Suspended. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
20 December 2019 The Department for Health and Social Care has asked NICE to conduct an appraisal of veliparib in combination for treating BRCA-positive, HER2-negative, breast cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid-August 2020 when we will write to you about how you can get involved.
23 October 2019 - 20 November 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
13 February 2018 In progress. Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance